Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06949826 · ClinicalTrials.gov registry record · Phase 4

Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery

A Phase 4 study of Opioid Use Disorder and Pain, Postoperative, sponsored by Jenna-Leigh Wilson.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT06949826: Recruiting Phase 4 study of Opioid Use Disorder and Pain, Postoperative, sponsored by Jenna-Leigh Wilson.

NCT06949826 is a Phase 4 study of Opioid Use Disorder and Pain, Postoperative that is actively recruiting participants, run by Jenna-Leigh Wilson. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06949826, a Phase 4 study of Opioid Use Disorder and Pain, Postoperative, is actively recruiting participants, sponsored by Jenna-Leigh Wilson.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.

Primary Outcome

After surgery, patients will record the total amount of opioid medication they consumed during the first post-operative week in their pain diary. In admitted patients, the electronic medical record will be reviewed to determine the morphine milligram equivalents of opioid consumed while admitted. Patients will also bring all their bottles and opioid prescriptions to their first post-operative clinic visit, at which point their total opioid consumption between surgery and their first post-operati

Interventions

  • DRUG Placebo Patch
  • DRUG Buprenorphine Transdermal System

Study Locations (1)

Missouri

  • Washington University in St. Louis/Barnes Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-21
Est. Completion 2027-06
Phase Phase 4
Jenna-Leigh Wilson

1 total trials

What NCT06949826 shows while recruiting

NCT06949826 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).

The record links to 5 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Patch is the first listed.

NCT06949826 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT06949826 about?

NCT06949826 is a clinical study titled "Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery". Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery...

What is the current status of trial NCT06949826?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-04-21. Estimated completion is 2027-06.

What conditions does trial NCT06949826 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Pain, Postoperative, Opioid Dependence, Opioid Analgesia, Ankle Fracture Surgery.

What interventions are being tested in trial NCT06949826?

The interventions under investigation include: Placebo Patch (DRUG), Buprenorphine Transdermal System (DRUG).

Who is sponsoring clinical trial NCT06949826?

This trial is sponsored by Jenna-Leigh Wilson, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06949826 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06949826's enrollment target sits among peer trials

100 130th of 257 higher than 121 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01773278 · 100 participants · Phase 2

    Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06949826, the US trial registry maintained by the National Library of Medicine. NCT06949826 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.